Business Context and Reporting Period
This Form 8-K, filed on June 6, 2016, by Zimmer Biomet Holdings, Inc. (Zimmer Biomet), reports the execution of an Agreement and Plan of Merger with LDR Holding Corporation (LDR). The transaction was announced via a joint press release on June 7, 2016.
Key Financial Metrics and Transaction Terms
- Acquisition Price: Zimmer Biomet will acquire all outstanding shares of LDR common stock at $37.00 per share in cash, net to the seller.
- Transaction Structure: The deal involves a tender offer by LH Merger Sub, Inc. (a wholly-owned subsidiary of Zimmer Biomet), followed by a merger where LDR survives as an indirect wholly-owned subsidiary of Zimmer Biomet.
- Financial Performance: This filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for either company. It references historical data in prior 10-K and 10-Q filings.
Material Changes and Outlook
The primary material change is the proposed acquisition of LDR. Management anticipates benefits including accretion and growth rates, though specific numerical guidance is not detailed in this text. The transaction is subject to customary closing conditions, including regulatory approvals and the successful completion of the tender offer.
Risks and Contingencies
- Regulatory and Closing Risks: The transaction may fail to close if necessary regulatory approvals are not obtained or if LDR stockholders do not tender sufficient shares.
- Integration Risks: There is a risk that the businesses will not integrate successfully or that the anticipated benefits will not be realized within the expected timeframe.
- Operational Disruption: The transaction could disrupt business relationships and operations.
- Market and Legal Risks: Potential negative effects on Zimmer Biomet's stock price, significant transaction costs, unknown liabilities, and the risk of litigation or regulatory actions.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the acquisition's benefits and timing, which are subject to substantial risks and uncertainties.
Investor Verification Checklist
- Verify the final tender offer price and any potential adjustments in the upcoming Schedule TO filing.
- Review the detailed financial projections and accretion analysis in the attached Investor Presentation (Exhibit 99.2).
- Monitor the status of regulatory approvals required for the merger to close.
- Assess the percentage of LDR shares tendered to determine if the transaction will proceed.
- Examine the full risk factors in the upcoming tender offer statement and LDR's Solicitation/Recommendation Statement (Schedule 14D-9).